Efficacy and Safety of Selumetinib in Adults with NF1 who have Symptomatic, Inoperable Plexiform Neurofibromas

Trial Identifier: D134BC00001
Sponsor: AstraZeneca
Collaborator:
Merck Sharp & Dohme Corp.
Start Date: November 2021
Primary Completion Date: August 2024
Study Completion Date: February 2029

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, 3000
AU St Leonards, AU, 2065
BR Porto Alegre, BR, 90035-903
BR Ribeirão Preto, BR, 14051-140
BR São Paulo, BR, 045202-001
CA, ON Toronto, ON, CA, M5G 2C4
CA, QC Montreal, QC, CA, H4A 3J1
CN Beijing, CN, 100730
CN Beijing, CN, 100070
CN Guangzhou, CN, 510060
CN shenyang, CN, 110001
DE Tübingen, DE, 72076
DE Würzburg, DE, 97080
ES Badalona, ES, 08916
ES Madrid, ES, 28041
FR Créteil, FR, 94000
FR Lyon, FR, 69008
FR Toulouse Cedex 09, FR, 31059
GB London, GB, SE1 9RT
GB Manchester, GB, M20 4BX
IT Milano, IT, 20133
IT Napoli, IT, 80131
IT ROMA, IT, 00165
JP Minato-ku, JP, 105-8471
JP Nagoya-shi, JP, 466-8560
JP Shinjuku-ku, JP, 160-8582
PL Bydgoszcz, PL, 85-094
RU Moscow, RU, 125412
RU Moscow, RU, 115522
US, FL Gainesville, FL, US, 32610
US, MD Rockville, MD, US, 20852
US, MO Saint Louis, MO, US, 63156
US, NY Commack, NY, US, 11725